U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07362238) titled 'Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)' on Jan. 15.
Brief Summary: This randomized, open-label study aim to compare the efficacy and safety of Daratumumab (anti-CD38 monoclonal antibody) with Rituximab in pediatric ITP patients.This study will be conducted in pediatric ITP patients who had not responded to or had relapsed after previous glucocorticoid treatment.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Immune Thrombocytopenia
Treatment
Intervention:
DRUG: Rituximab
All subjects were randomly assigned to group A (active comparator) and group ...